Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|14|3|369-381

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.14, Iss.3, 2014-02, pp. : 369-381

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mass spectrometry-based clinical proteomics

By Pusch Wolfgang Flocco Mark T Leung Sau-Mei Thiele Herbert Kostrzewa Markus

Pharmacogenomics, Vol. 4, Iss. 4, 2003-07 ,pp. : 463-476

Future Medicine

Access to resources Recommend Favorite

Non-oral drug delivery in Parkinson’s disease: a summary from the symposium at the 7th International Congress of Parkinson’s Disease and Movement Disorders

By Behrens Stephan Sommerville Kenneth

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 4, 2003-04 ,pp. : 595-599

Informa Healthcare

Access to resources Recommend Favorite

MALDI-TOF mass spectrometry-based SNP genotyping

By Pusch Wolfgang Wurmbach Jan-Henner Thiele Herbert Kostrzewa Markus

Pharmacogenomics, Vol. 3, Iss. 4, 2002-07 ,pp. : 537-548

Future Medicine

Access to resources Recommend Favorite

Subcutaneous Apomorphine: An Evidence-Based Review of its Use in Parkinsons Disease

By Dirk Deleu

Drugs & Aging, Vol. 21, Iss. 11, 2004-01 ,pp. : 687-709

Adis International

Access to resources Recommend Favorite

Prospects for the treatment of Parkinson’s disease using neural grafts

By Barker R.A.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 5, 2000-07 ,pp. : 889-902

Informa Healthcare

Access to resources Recommend Favorite